

DOCKET NO.: ISIS-5582  
 Application No.: 10/510,667  
 Restriction Requirement mailed: September 1, 2006


PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**


**What is Claimed is:**

1. (currently amended) An oligomeric compound having the formula:



wherein:

each  $Bx$  is, independently, a heterocyclic base moiety;  
J1, J3 and each J2 is, independently, hydrogen  $T_1$  and  $T_2$  are each independently, hydroxyl, a protected hydroxyl, an oligonucleotide, an oligonucleoside or a modified phosphate group having the structure formula:



wherein

one of  $Q_1$  and  $Q_2$  is S and the other of  $Q_1$  and  $Q_2$  is O;  
 $Q_3$  is OH or  $CH_3$ ;

$R_1$ ,  $R_3$  and each  $R_2$  is, independently, hydrogen, hydroxyl, a sugar substituent group, a protected sugar substituent group or said modified phosphate group;

DOCKET NO.: ISIS-5582  
Application No.: 10/510,667  
Restriction Requirement mailed: September 1, 2006

PATENT

~~each T<sub>1</sub> and T<sub>2</sub> is, independently, hydroxyl, a protected hydroxyl, an oligonucleotide, an oligonucleoside or said modified phosphate group;~~

each X<sub>1</sub> and X<sub>2</sub> is, independently, O or S wherein at least one X<sub>1</sub> is S;

n is from 3 to 48; and

wherein at least one of T<sub>1</sub> or T<sub>2</sub> is said modified phosphate group.

2. (original) The oligomeric compound of claim 1 wherein Q<sub>1</sub> is S.

3. (original) The oligomeric compound of claim 1 wherein Q<sub>2</sub> is S.

4. (original) The oligomeric compound of claim 1 wherein Q<sub>3</sub> is CH<sub>3</sub>.

Claims 5-10 (canceled)

11. (original) The oligomeric compound of claim 1 wherein R<sub>1</sub>, R<sub>3</sub> and each R<sub>2</sub> is hydrogen.

12. (original) The oligomeric compound of claim 1 wherein R<sub>1</sub>, R<sub>3</sub> and each R<sub>2</sub> is hydroxyl.

13. (currently amended) The oligomeric compound of claim 1 wherein R<sub>1</sub>, R<sub>3</sub> and each R<sub>2</sub> is, independently, hydrogen, hydroxyl, a sugar substituent group or a protected sugar substituent group.

14. (original) The oligomeric compound of claim 1 wherein at least one of R<sub>1</sub>, R<sub>2</sub> or R<sub>3</sub> is an optionally protected sugar substituent group.

15. (original) The oligomeric compound of claim 1 wherein each X<sub>2</sub> is S.

16. (original) The oligomeric compound of claim 1 wherein each heterocyclic base moiety is, independently, adenine, cytosine, 5-methylcytosine, thymine, uracil, guanine or 2-aminoadenine.

DOCKET NO.: ISIS-5582  
Application No.: 10/510,667  
Restriction Requirement mailed: September 1, 2006

PATENT

17. (original) The oligomeric compound of claim 1 wherein n is from about 8 to about 30.

18. (original) The oligomeric compound of claim 1 wherein n is from about 15 to 25.

19. (withdrawn) A method of treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligomeric compound of claim 1.

20. (original) A pharmaceutical composition comprising:

a pharmaceutically effective amount of an oligomeric compound of claim 1; and  
a pharmaceutically acceptable diluent or carrier.

21. (withdrawn) A method of modifying *in vitro* a nucleic acid, comprising contacting a test solution containing RNase H and said nucleic acid with an oligomeric compound of claim 1.

22. (withdrawn) A method of concurrently enhancing hybridization and RNase H activation in a organism comprising contacting the organism with an oligomeric compound of claim 1.

23. (withdrawn) A method comprising contacting a cell with an oligomeric compound of claim 1.

Claims 24-41 (canceled)